Author:
Kacimi Salah Eddine O.,Sukaina Mahnoor,Elgenidy Anas,Farahat Ramadan Abdelmoez,Cheema Huzaifa A.,Benmelouka Amira Y.,Awad Dina M.,Belaouni Hadj Ahmed,Abdelli Moustafa K.E,Tidjane Anisse,Mesli Nabil Smain,Shah Jaffer,Setti Mounir Ould,Afifi Ahmed M.,Ghozy Sherief,
Abstract
AbstractBackgroundDiabetic Muslims who choose to fast during Ramadan encounter major risks such as hyperglycemia, hypoglycemia, diabetic ketoacidosis, and dehydration. Recently, newer antidiabetic agents have been found to be less likely to cause hypoglycemic emergencies. This meta-analysis aimed to present collective and conclusive results from major randomized controlled trials (RCTs) to determine the risk of hypoglycemia among patients taking oral antidiabetics during Ramadan.MethodsWe searched PubMed, Web of Science, and Google Scholar for RCTs. We performed a frequentist network meta-analysis using the “netmeta” package of R software version 4.1.1 to investigate the risk of developing hypoglycemia after taking oral antidiabetic drugs during Ramadan.ResultsNine RCTs with a total of 3464 patients were included in the final analysis. In the comparison of all antidiabetic drug classes with sulfonylureas, SGLT-2 inhibitors were associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-0.78; P-score, 0.909), followed by GLP-1 agonists (RR, 0.31; 95% CI, 0.17-0.56; P-score, 0.799), and DDP-4 inhibitors (RR, 0.57; 95% CI, 0.43-0.75; P-score, 0.483). When comparing individual drugs, dapagliflozin was associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-0.78; P-score, 0.874), followed by lixisenatide (RR, 0.25; 95% CI, 0.09-0.71; P-score, 0.813), liraglutide (RR, 0.34; 95% CI, 0.17-0.69; P-score, 0.715), and sitagliptin (RR. 0.51; 95% CI, 0.37-0.71; P-score, 0.515).ConclusionSGLT-2 inhibitors are associated with the least documented hypoglycemic events and adverse outcomes compared with other oral hypoglycemic drugs. These findings could have considerable public health and clinical implications when extrapolated to the global Muslim population with a similar clinical background.Abstract Figure
Publisher
Cold Spring Harbor Laboratory
Reference38 articles.
1. Follow-up of glycemic index before and after Ramadan fasting in type 2 diabetes patients under antidiabetic medications;Ann Pharm Françaises,2019
2. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients;J Diabetes Res,2016
3. Diabetes and Ramadan n.d. https://idf.org/our-activities/education/diabetes-and-ramadan.html (accessed May 27, 2022).
4. Almalki MH , Alshahrani F. Options for Controlling Type 2 Diabetes during Ramadan. Front Endocrinol 2016;7.
5. Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients;Diabetes Metab Syndr Obes,2015